BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34171513)

  • 1. Hyperkyphosis is not dependent on bone mass and quality in the mouse model of Marfan syndrome.
    Souza RB; Kawahara EI; Farinha-Arcieri LE; Gyuricza IG; Neofiti-Papi B; Miranda-Rodrigues M; Teixeira MBCG; Fernandes GR; Lemes RB; Reinhardt DP; Gouveia CH; Pereira LV
    Bone; 2021 Nov; 152():116073. PubMed ID: 34171513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mgΔ
    Souza RB; Gyuricza IG; Cassiano LL; Farinha-Arcieri LE; Alvim Liberatore AM; Schuindt do Carmo S; Caldeira W; Cruz MV; Ribeiro AF; Tedesco RC; Reinhardt DP; Smith R; Jun Koh IH; Pereira LV
    Exp Eye Res; 2021 Mar; 204():108461. PubMed ID: 33516761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.
    Takeda N; Yagi H; Hara H; Fujiwara T; Fujita D; Nawata K; Inuzuka R; Taniguchi Y; Harada M; Toko H; Akazawa H; Komuro I
    Int Heart J; 2016 May; 57(3):271-7. PubMed ID: 27181042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aortopathy in a Mouse Model of Marfan Syndrome Is Not Mediated by Altered Transforming Growth Factor β Signaling.
    Wei H; Hu JH; Angelov SN; Fox K; Yan J; Enstrom R; Smith A; Dichek DA
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28119285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
    Nistala H; Lee-Arteaga S; Carta L; Cook JR; Smaldone S; Siciliano G; Rifkin AN; Dietz HC; Rifkin DB; Ramirez F
    Hum Mol Genet; 2010 Dec; 19(24):4790-8. PubMed ID: 20871099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating transforming growth factor-beta in Marfan syndrome.
    Matt P; Schoenhoff F; Habashi J; Holm T; Van Erp C; Loch D; Carlson OD; Griswold BF; Fu Q; De Backer J; Loeys B; Huso DL; McDonnell NB; Van Eyk JE; Dietz HC;
    Circulation; 2009 Aug; 120(6):526-32. PubMed ID: 19635970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-29b participates in early aneurysm development in Marfan syndrome.
    Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
    Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NADPH oxidase 4 attenuates cerebral artery changes during the progression of Marfan syndrome.
    Onetti Y; Meirelles T; Dantas AP; Schröder K; Vila E; Egea G; Jiménez-Altayó F
    Am J Physiol Heart Circ Physiol; 2016 May; 310(9):H1081-90. PubMed ID: 26945079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous activation of BMP-2 signaling overcomes TGFβ-mediated inhibition of osteogenesis in Marfan embryonic stem cells and Marfan patient-specific induced pluripotent stem cells.
    Quarto N; Li S; Renda A; Longaker MT
    Stem Cells; 2012 Dec; 30(12):2709-19. PubMed ID: 23037987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Bones Deficient in Fibrillin-1 Microfibrils Reveals Pronounced Sex Differences.
    Altinbas L; Bormann N; Lehmann D; Jeuthe S; Wulsten D; Kornak U; Robinson PN; Wildemann B; Kararigas G
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31805661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle and Bone Impairment in Children With Marfan Syndrome: Correlation With Age and FBN1 Genotype.
    Haine E; Salles JP; Khau Van Kien P; Conte-Auriol F; Gennero I; Plancke A; Julia S; Dulac Y; Tauber M; Edouard T
    J Bone Miner Res; 2015 Aug; 30(8):1369-76. PubMed ID: 25656438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model of Severe Marfan Syndrome.
    Lee JJ; Galatioto J; Rao S; Ramirez F; Costa KD
    Ann Biomed Eng; 2016 Oct; 44(10):2994-3006. PubMed ID: 27090893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated Marfan syndrome model recapitulates established signaling pathways.
    Gensicke NM; Cavanaugh NB; Andersen ND; Huang T; Qian L; Dyle MC; Turek JW
    J Thorac Cardiovasc Surg; 2020 May; 159(5):1719-1726. PubMed ID: 31272746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Molecular Genetics of Marfan Syndrome.
    Du Q; Zhang D; Zhuang Y; Xia Q; Wen T; Jia H
    Int J Med Sci; 2021; 18(13):2752-2766. PubMed ID: 34220303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.
    Hibender S; Franken R; van Roomen C; Ter Braake A; van der Made I; Schermer EE; Gunst Q; van den Hoff MJ; Lutgens E; Pinto YM; Groenink M; Zwinderman AH; Mulder BJ; de Vries CJ; de Waard V
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1618-26. PubMed ID: 27283746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Loci Modulating the Cardiovascular and Skeletal Phenotypes of Marfan Syndrome in Mice.
    Fernandes GR; Massironi SM; Pereira LV
    Sci Rep; 2016 Mar; 6():22426. PubMed ID: 26927851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three Novel Variants identified in FBN1 and TGFBR2 in seven Iranian families with suspected Marfan syndrome.
    Bitarafan F; Razmara E; Khodaeian M; Keramatipour M; Kalhor A; Jafarinia E; Garshasbi M
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1274. PubMed ID: 32431097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress towards a molecular understanding of Marfan syndrome.
    Dietz HC; Loeys B; Carta L; Ramirez F
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):4-9. PubMed ID: 16273535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.
    Cohn RD; van Erp C; Habashi JP; Soleimani AA; Klein EC; Lisi MT; Gamradt M; ap Rhys CM; Holm TM; Loeys BL; Ramirez F; Judge DP; Ward CW; Dietz HC
    Nat Med; 2007 Feb; 13(2):204-10. PubMed ID: 17237794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.